Cargando…
P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB
Autores principales: | Palandri, F., Bartoletti, D., Elli, E. M., Auteri, G., Bonifacio, M., Benevolo, G., Heidel, F., Trawinska, M. M., Rossi, E., Bosi, C., Tieghi, A., Tiribelli, M., Iurlo, A., Polverelli, N., Caocci, G., Binotto, G., Cavazzini, F., Beggiato, E., Cilloni, D., Tatarelli, C., Mendicino, F., Miglino, M., Bocchia, M., Crugnola, M., Mazzoni, C., Romagnoli, A. D., Rindone, G., Ceglie, S., D’Addio, A., Santoni, E., Cattaneo, D., Lemoli, R. M., Krampera, M., Cuneo, A., Semenzato, G., Latagliata, R., Abruzzese, E., Vianelli, N., Cavo, M., Andriani, A., De Stefano, V., Palumbo, G., Breccia, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431186/ http://dx.doi.org/10.1097/01.HS9.0000846912.37527.f8 |
Ejemplares similares
-
P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
por: Palandri, F., et al.
Publicado: (2022) -
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
por: Palandri, Francesca, et al.
Publicado: (2023) -
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study
por: Palandri, Francesca, et al.
Publicado: (2023) -
Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?
por: Lemoli, Roberto M., et al.
Publicado: (2011) -
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2022)